The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Merck will record a pre-tax charge relating to the upfront payment of $588 million
This facility marks a significant milestone in transforming the global food industr
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Merck has also decided to end the favezelimab clinical development program
Subscribe To Our Newsletter & Stay Updated
